News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Heart Drug Wins Approval in China



11/30/2012 8:05:54 AM

AstraZeneca has won approval for its new heart drug Brilinta in China, an increasingly important market for the British pharmaceuticals group. China's State Food and Drug Administration has issued an drug import license for the product, meaning it will now be available for treating patients with acute coronary syndrome in the country, the company said on Thursday. Brilinta has proved better than the cheaper generic medicine clopidogrel in preventing the recurrence of heart attacks, but its sales to date in markets around the world have been disappointing.

Read at Reuters
Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES